Latest Breaking News On - Kadmon - Page 2 : comparemela.com

KDMN Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Kadmon Holdings, Inc Investors of Class Action and Lead Plaintiff Deadline: June 2, 2021

NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) Attorney Advertising Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Kadmon Holdings, Inc. ("Kadmon" or the "Company") (NASDAQ: KDMN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Kadmon securities between October 1, 2020 and March 10, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/kdmn. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose that: (1) the Belumosudil NDA was incomplete and/or deficient; (2) the additional new data that the Company submitted in support of

Kadmon holdingsAdvertising bronsteinGewirtz grossmanPeretz bronsteinClass action lawsuitThe company

Kadmon Holdings, Inc : Kadmon Announces Publication of Phase 2a Clinical Trial Results of Belumosudil for cGVHD in the Journal of Clinical Oncology

(0) NEW YORK, NY / ACCESSWIRE / April 21, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the publication of results from KD025-208, the Phase 2a clinical trial of belumosudil (KD025) for chronic graft-versus-host disease (cGVHD). The results were published in the Journal of Clinical Oncology. A New Drug Application (NDA) for belumosudil is currently under Priority Review by the U.S Food and Drug Administration (FDA) for the treatment of patients with cGVHD, with a Prescription Drug User Fee Act (PDUFA) goal date of August 30, 2021. The results from our first clinical study in cGVHD demonstrated that belumosudil achieves meaningful, long-lasting responses and is very well tolerated in refractory cGVHD patients, said Harlan W. Waksal, M.D., President and CEO of Kadmon. These positive results were replicated in the ROCKstar pivotal trial and support belumosudil s ability to offer meaningful clinical benefit, if approved, to patients with cGVHD, for which new therapies

United statesHarlanw waksalEllen cavaleriExchange commissionKadmon holdings incDrug administrationKadmon holdingsNew drug applicationPriority reviewPrescription drug user fee actOverall response rateChronic graft versus host diseaseTime oncology reviewProject orbisBreakthrough therapy designationOrphan drug designation

Kadmon Holdings, Inc : Kadmon Doses First Patient in Open-Label Phase 2 Clinical Trial of Belumosudil in Systemic Sclerosis

(0) NEW YORK, NY / ACCESSWIRE / April 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the first patient has been dosed in an open-label Phase 2 clinical trial of belumosudil, the Company s ROCK2 inhibitor, in patients with diffuse cutaneous systemic sclerosis (dcSSc), a chronic immune disorder characterized by fibrosis of the skin and internal organs. The Phase 2 study (KD025-215) will enroll up to 15 adults with dcSSc who will receive orally administered belumosudil 200 mg twice daily (BID). The primary endpoint is the Combined Response Index for Systemic Sclerosis (CRISS) score. The Company plans to present initial data from this study by year-end 2021. In addition to the KD025-215 trial, an ongoing, double-blind, placebo-controlled Phase 2 clinical trial of belumosudil (KD025-209) is currently enrolling 60 adults with dcSSc. Patients are randomized to receive belumosudil 200 mg once daily (QD), belumosudil 200 mg BID or placebo.

United statesHarlanw waksalEllen cavaleriExchange commissionKadmon holdings incDrug administrationKadmon holdingsCombined response indexSystemic sclerosisOrphan drug designationPriority reviewNew drug applicationPrescription drug user fee actTime oncology reviewProject orbisBreakthrough therapy designation

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Kadmon Holdings, Inc (KDMN) and Encourages Investors to Contact the Firm

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Kadmon Holdings, Inc (KDMN) and Encourages Investors to Contact the Firm
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Gewirtz grossmanKadmon holdingsPeretz bronsteinகெவிரத்ஜ் மொத்த மனிதர்பெரெட்ஸ் ப்ரோன்ஸ்டீன்

Kadmon Holdings, Inc : Kadmon to Present at Upcoming Investor Conferences

Kadmon Holdings, Inc.: Kadmon to Present at Upcoming Investor Conferences Raymond James 42 Date: Wednesday, March 3, 2021 Time: 4:40pm ET Presentation viewable starting on Tuesday, March 9, 2021 at 7:00am ET Oppenheimer s 31 Time: 2:30pm ET Live audio webcasts of the presentations may be accessed on the Investors section of the Kadmon website at www.kadmon.com. Replays of the webcasts will be available for 90 days. About Kadmon Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Kadmon s clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. Forward-Looking Statements This press release contains forward-looking statements. Such statements may be preceded by the words may, will, should, expects, plans, anticipates, could, intends, targets, projects, contemplates, believes, estimates, predicts, potential

United statesRaymond jamesHarlanw waksalEllen cavaleriExchange commissionKadmon holdings incHc wainwright global life sciences conferenceKadmon holdingsChief executive officerAnnual institutional investorsAnnual healthcareAnnual reportஒன்றுபட்டது மாநிலங்களில்ரேமஂட் ஜேம்ஸ்பரிமாற்றம் தரகுஹ்ஸீ வேந்‌ரைட் உலகளாவிய வாழ்க்கை அறிவியல் மாநாடு